{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:04:50Z","timestamp":1792587890340,"version":"4.5.0"},"reference-count":48,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,6,25]],"date-time":"2009-06-25T00:00:00Z","timestamp":1245888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> No randomized controlled trial (RCT) has compared all European\u2010licensed standard\u2010 and double\u2010dose PPIs for the healing of severe erosive oesophagitis.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To compare the effectiveness of licensed doses of PPIs for healing severe erosive oesophagitis (i.e. esomeprazole 40\u2003mg, lansoprazole 30\u2003mg, omeprazole 20\u2003mg and 40\u2003mg, pantoprazole 40\u2003mg and rabeprazole 20\u2003mg).<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Systematic review of CENTRAL, EMBASE and MEDLINE for RCTs in patients with erosive oesophagitis (completed October 2008). Endoscopically verified healing rates at 4 and 8\u2003weeks were extracted and re\u2010calculated if not analysed by intention\u2010to\u2010treat. A mixed treatment comparison was used to combine direct treatment comparisons with indirect trial evidence while maintaining randomization. Odds ratios (OR) are reported compared to omeprazole 20\u2003mg.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A total of 3021 papers were identified in the literature search; 12 were of sufficient quality to be included in the analysis. Insufficient data were available to included rabeprazole. Esomeprazole 40\u2003mg was found to provide significantly higher healing rates at 4\u2003weeks [OR 1.84, 95% Credible Interval (95% CrI): 1.50 to 2.22] and 8\u2003weeks (OR 1.91, 95% CrI: 1.13 to 2.88). No other PPI investigated had significantly higher healing rates than omeprazole 20\u2003mg.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Esomeprazole 40\u2003mg consistently demonstrates higher healing rates compared with licensed standard\u2010 and double\u2010dose PPIs.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2009.04077.x","type":"journal-article","created":{"date-parts":[[2009,6,25]],"date-time":"2009-06-25T14:37:09Z","timestamp":1245940629000},"page":"547-556","source":"Crossref","is-referenced-by-count":32,"title":["Systematic review: standard\u2010 and double\u2010dose proton pump inhibitors for the healing of severe erosive oesophagitis \u2013 a mixed treatment comparison of randomized controlled trials"],"prefix":"10.1111","volume":"30","author":[{"given":"S. J.","family":"EDWARDS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"LIND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"LUNDELL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"DAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,8,18]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.5.649"},{"key":"e_1_2_8_3_2","unstructured":"MooreRA PhillipsC.Reflux oesophagitis: quantitative systematic review of the evidence of effectiveness of proton pump inhibitors and histamine antagonists. Bandolier 1999. Available at:http:\/\/www.medicine.ox.ac.uk\/bandolier\/bandopubs\/gordf\/gord.html(Last accessed April 2009)"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9178669"},{"key":"e_1_2_8_5_2","unstructured":"Losec\u00ae MUPS\u00ae.Losec\u00ae MUPS\u00ae Tablets 10\u2003mg 20\u2003mg & 40\u2003mg SmPC. Available at: emc.medicines.org.uk\/medicine\/10841\/SPC\/Losec+MUPS+Tablets+10mg%2c+20mg+%26+40mg\/ (Last accessed March 2009)."},{"key":"e_1_2_8_6_2","unstructured":"Nexium\u00ae.Nexium\u00ae 20\u2003mg and 40\u2003mg Tablets SmPC. Available at: emc.medicines.org.uk\/medicine\/14307\/SPC\/Nexium+20mg+%26+40mg+Tablets\/ (Last accessed March 2009)."},{"key":"e_1_2_8_7_2","unstructured":"Pariet.Pariet 10\u2003mg & 20\u2003mg Tablets SmPC. Available at: emc.medicines.org.uk\/medicine\/2577\/SPC\/Pariet+10mg+%26+20mg\/ (Last accessed March 2009)."},{"key":"e_1_2_8_8_2","unstructured":"Protium\u00ae.Protium\u00ae 40\u2003mg Tablet SmPC. Available at:http:\/\/www.emc.medicines.org.uk\/medicine\/13055\/SPC\/Protium+40+mg+tablet\/(Last accessed March 2009)."},{"key":"e_1_2_8_9_2","unstructured":"Zoton\u00ae FasTab\u00ae.Zoton\u00ae FasTab\u00ae SmPC. Available at: emc.medicines.org.uk\/medicine\/10426\/SPC\/Zoton+FasTab\/ (Last accessed March 2009)."},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01128.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01562.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01756.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03074.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.09.013"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00125.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.172"},{"key":"e_1_2_8_17_2","unstructured":"NICE Guide to the methods of technology appraisal June 2008. Available at:http:\/\/www.nice.org.uk\/media\/B52\/A7\/TAMethodsGuideUpdatedJune2008.pdf(Last accessed March 2009)"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02072.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1566"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1201"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2534"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9868.00353"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018598421607"},{"key":"e_1_2_8_27_2","first-page":"1749","article-title":"Efficacy and safety of lansoprazole in the treatment of reflux oesophagitis","volume":"91","author":"Castell DO","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05532.x"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02339.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90162-X"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200222020-00004"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00856.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02368.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.56198000.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199611000-00013"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03600.x"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91790-B"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-9062-4"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1147"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520290060030"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08783.x"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015009300955"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00438.x"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03190.x"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200626010-00003"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00363.x"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00238.x"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018822532736"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02606.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2009.04077.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2009.04077.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:09:24Z","timestamp":1697227764000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2009.04077.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,18]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1365-2036.2009.04077.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04077.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,18]]}}}